| Primary Identifier | MGI:2387680 | Allele Type | Transgenic |
| Attribute String | Humanized sequence, Inducible, Inserted expressed sequence | Gene | Tg(tetO-BCR/ABL1)2Dgt |
| Strain of Origin | FVB/N | Induced With | doxycycline/tetracycline |
| Is Recombinase | false | Is Wild Type | false |
| description | This record is also representative of lines 3 and 4 that were also generated; all of these lines exhibit a similar phenotype in combination with Tg(MMTVtTA)1Mam. Bitransgenic mice with this transgene in combination with Tg(MMTVtTA)1Mam, when tetracycline administration is stopped, are models for B cell acute lymphoblastic leukemia (ALL); line 2 exhibits the greatest leukemia susceptibility (Figure 1). (J:72377) |
| molecularNote | The transgene contains a cDNA encoding the human p210 BCR-ABL1 fusion protein (B3A2 form; J:86227) under transcriptional control of the tetracycline-responsive element (tetO; also called TRE) fused to a minimal cytomegalovirus (CMV) promoter. In doubly transgenic mice expressing a tetracycline transactivator or reverse transactivator protein under the control of a ubiquitous or tissue-specific promoter, expression of the BCL-ABL1 fusion gene can be controlled temporally by withdrawal or administration of a tetracycline analog. |
